|
Catalogue Number
|
156429 |
|
Antigen/Gene or Protein Targets
|
IDH1
|
|
Disease Keywords
|
Glial tumor formation
|
|
Relevance
|
An in vivo Isocitrate Dehydrogenase (IDH-1) glioma mouse xenograft model has been developed to further study effective therapies for IDH mutations characterized by increased DNA methylation and production of the common oncometabolite, 2-HG. Difficult grafting cell-culture techniques and current engineered cell line quality have limited additional laboratory studies; however, this model was developed directly from a WHO grade III- glial cell positive cancer patient tissue (JHH273) with a confirmed IDH mutation through DNA sequencing and maintains IDH-1 mutation features observed in human primary glial brain tumors. Additionally, when models were exposed to a demethlyating agent, 5-azacytidine, a reduction in methylation and tumor growth was observed opening the door for more clinical analysis. This model meets a critical need to test drug agents targeting mechanisms involved in glial tumor formation.
|
|
Growth/Phenotype Keywords
|
4–6-week old female athymic nude mice
|
|
Mouse Genetic Background/Cross History
|
4–6-week old female athymic nude mice
|
|
Research Area
|
Cancer, Drug Discovery & Development
|
